RBR-9wkw73j
Recruiting
未知
Randomized clinical study of the use of intravitreal injection of Bevacizumab inprimary open-angle glaucoma.
nião Metropolitana de Educação e Cultura0 sitesMay 30, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- nião Metropolitana de Educação e Cultura
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The inclusion criteria will be: Primary Open Angle patients over 40 years of age, with uncontrolled Intraocular pressure (IOP) on maximum tolerated medical therapy, requiring trabeculectomy. Indications for trabeculectomy will include eyes where IOP measurements associated with a high probability of glaucoma progression or eyes where a deterioration of the visual field or the optic disk compatible with progressive glaucomatous damage was documented by the examining physician.
Exclusion Criteria
- •Patients will be excluded if known to have an allergic reaction either to MMC or BZM, had undergone previous intraocular surgery (except uneventful cataract surgery); were diagnosed with normal tension glaucoma, angle closure glaucoma or secondary glaucomas; had prior history of ocular infection, uveitis or ocular trauma; were pregnant or breast\-feeding women; had a history of uncontrolled diabetes and/or systemic hypertension or any other systemic condition that could be influenced by BZM injections
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Pilot study investigating the use of Intravitreal Triamcinolone prior to macular laser for Clinically Significant Diabetic Macular Oedema - CSMO and triamcinoloneMacular oedema affects 29% of diabetic patients and is the main cause of visual impairment. Previous studies show that diffuse macular oedema carries a particularly poor prognosis despite laser photocoagulation.EUCTR2004-005043-97-GBSt Mary's NHS Trust50
Active, not recruiting
Phase 1
A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa.Retinitis Pigmetosa.MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Body processes [G] - Genetic Phenomena [G05]EUCTR2016-002523-28-GBMoorfields Eye Hospital1
Completed
Not Applicable
Evaluation of the efficacy and safety of intravitreal injection of ranibizumab every other month for age-related macular degeneratioage-related macular degenerationJPRN-UMIN000005691Department of Ophthalmology, Shiga University of Medical Science40
Completed
Not Applicable
Evaluation of the efficacy and safety of intravitreal bimonthly injection of aflibercept for age-related macular degeneratioage-related macular degenerationJPRN-UMIN000010312Department of Ophthalmology, Shiga University of Medical Science40
Completed
Phase 3
a clinical trial to find the most appropriate maintenance fluid in children with central nervous system infectioHealth Condition 1: null- to compare the incidence of hyponatremia with maintenance fluids ( isotonic and hypotonic) in children with CNS infectionsCTRI/2012/05/002637Kalawati Saran Chiuldrens Hospital90